These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 38652971

  • 1. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L, Li Y, Hu X, Gong Y, Chen J, Huang P, Tan Z, Ge M, Pan Z.
    Int Immunopharmacol; 2024 May 30; 133():112102. PubMed ID: 38652971
    [Abstract] [Full Text] [Related]

  • 2. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S.
    Br J Cancer; 2018 Nov 30; 119(10):1223-1232. PubMed ID: 30327563
    [Abstract] [Full Text] [Related]

  • 3. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, Greenberg JA, Zhang T, He B, Finnerty BM, Zarnegar R, Jin MM, Scognamiglio T, Dephoure N, Fahey T, Min IM.
    Thyroid; 2021 Oct 30; 31(10):1481-1493. PubMed ID: 34078123
    [Abstract] [Full Text] [Related]

  • 4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM, Roelli MA, Forster S, Wasmer MH, Brühl F, Maire RS, Di Pancrazio S, Ruepp MD, Giger R, Perren A, Schmitt AM, Krebs P, Charles RP, Dettmer MS.
    Thyroid; 2019 Jul 30; 29(7):979-992. PubMed ID: 30938231
    [Abstract] [Full Text] [Related]

  • 5. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S, Carnazza M, Jarboe T, DeSouza N, Li XM, Moscatello A, Geliebter J, Tiwari RK.
    Adv Exp Med Biol; 2021 Jul 30; 1350():33-66. PubMed ID: 34888843
    [Abstract] [Full Text] [Related]

  • 6. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.
    Int J Cancer; 2019 May 01; 144(9):2266-2278. PubMed ID: 30515783
    [Abstract] [Full Text] [Related]

  • 7. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ, Ye WD, Yu PC, Tan LC, Shi X, Chen XF, He C, Hu JQ, Wei WJ, Lu ZW, Qu N, Wang Y, Ji QH, Ji DM, Wang YL.
    JCI Insight; 2024 Mar 07; 9(8):. PubMed ID: 38478516
    [Abstract] [Full Text] [Related]

  • 8. IL2RA+VSIG4+ tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer.
    Pan Z, Bao L, Lu X, Hu X, Li L, Chen J, Jin T, Zhang Y, Tan Z, Huang P, Ge M.
    Biochim Biophys Acta Mol Basis Dis; 2023 Jan 01; 1869(1):166591. PubMed ID: 36328145
    [Abstract] [Full Text] [Related]

  • 9. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway.
    Wang X, Zhang Y, Zheng J, Yao C, Lu X.
    Cancer Immunol Immunother; 2021 Aug 01; 70(8):2235-2245. PubMed ID: 33486611
    [Abstract] [Full Text] [Related]

  • 10. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
    Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ, Jin MM.
    Clin Cancer Res; 2017 Dec 15; 23(24):7569-7583. PubMed ID: 29025766
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X.
    Theranostics; 2021 Dec 15; 11(7):3089-3108. PubMed ID: 33537076
    [Abstract] [Full Text] [Related]

  • 13. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, Stefanova D, Christos PJ, Scognamiglio T, Tassler AB, Zarnegar R, Fahey TJ, Jin MM, Min IM.
    Clin Cancer Res; 2020 Nov 15; 26(22):6003-6016. PubMed ID: 32887724
    [Abstract] [Full Text] [Related]

  • 14. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment.
    Pan Z, Xu T, Bao L, Hu X, Jin T, Chen J, Chen J, Qian Y, Lu X, Li L, Zheng G, Zhang Y, Zou X, Song F, Zheng C, Jiang L, Wang J, Tan Z, Huang P, Ge M.
    Mol Cancer; 2022 Oct 03; 21(1):190. PubMed ID: 36192735
    [Abstract] [Full Text] [Related]

  • 15. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, Gigantino V, Franco R, Marone G, Portella G.
    Oncotarget; 2016 Jan 12; 7(2):1500-15. PubMed ID: 26625205
    [Abstract] [Full Text] [Related]

  • 16. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
    Ahn J, Jin M, Song E, Ryu YM, Song DE, Kim SY, Kim TY, Kim WB, Shong YK, Jeon MJ, Kim WG.
    Thyroid; 2021 Jan 12; 31(1):61-67. PubMed ID: 32611231
    [Abstract] [Full Text] [Related]

  • 17. The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis.
    Jin T, Wang W, Ge L, Li X, Ge M.
    Endocrine; 2023 Dec 12; 82(3):590-601. PubMed ID: 37480496
    [Abstract] [Full Text] [Related]

  • 18. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L, Liu J, Zhang Y, Su A, Tang M, Xing Z, He T, Wei T, Li Z, Wu W.
    Phytomedicine; 2024 Jul 12; 129():155670. PubMed ID: 38704915
    [Abstract] [Full Text] [Related]

  • 19. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
    Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, Castagna MG, Toti P.
    Endocrine; 2019 Apr 12; 64(1):122-129. PubMed ID: 30762153
    [Abstract] [Full Text] [Related]

  • 20. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR.
    J Immunother Cancer; 2020 Apr 12; 8(1):. PubMed ID: 32303618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.